Virologic and Immunologic Parameters that Predict Clinical Response of AIDS-Associated Kaposi's Sarcoma to Highly Active Antiretroviral Therapy

Babcock, 1999, Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients, J Exp Med, 190, 567, 10.1084/jem.190.4.567 Boivin, 2000, Evaluation of the human herpesvirus 8 DNA load in blood and Kaposi's sarcoma skin lesions from AIDS patients on highly active antiretroviral therapy, Aids, 14, 1907, 10.1097/00002030-200009080-00004 Bower, 1999, Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma, Aids, 13, 2105, 10.1097/00002030-199910220-00014 Cattelan, 2001, Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome, J Natl Cancer Inst Monogr, 22, 44 Chene, 1998, Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine, Aids, 12, 2313, 10.1097/00002030-199817000-00013 Dupin, 1999, The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma, Br J Dermatol, 140, 875, 10.1046/j.1365-2133.1999.02818.x Dupont, 2000, Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine [In Process Citation], Aids, 14, 987, 10.1097/00002030-200005260-00010 Gardella, 1984, Detection of circular and linear herpesvirus DNA molecules in mammalian cells by gel electrophoresis, J Virol, 50, 248, 10.1128/JVI.50.1.248-254.1984 Henry, 1999, Infection of circulating CD34+ cells by HHV-8 in patients with Kaposi's sarcoma, J Invest Dermatol, 113, 613, 10.1046/j.1523-1747.1999.00733.x Hermans, 1997, Survival of European patients with Kaposi's sarcoma as AIDS-defining condition during the first decade of AIDS. AIDS in Europe Study Group, Aids, 11, 525, 10.1097/00002030-199704000-00017 Kennedy, 1997, HHV8 and Kaposi's sarcoma: a time cohort study [published erratum appears in Mol Pathol 5: 167 1997], Mol Pathol, 50, 96, 10.1136/mp.50.2.96 Krown, 1989, Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee, J Clin Oncol, 7, 1201, 10.1200/JCO.1989.7.9.1201 Krown, 1997, AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee, J Clin Oncol, 15, 3085, 10.1200/JCO.1997.15.9.3085 Lallemand, 2000, Quantitative analysis of human herpesvirus 8 viral load using a real-time PCR assay, J Clin Microbiol, 38, 1404, 10.1128/JCM.38.4.1404-1408.2000 Lebbe, 1998, Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma, Aids, 12, F45, 10.1097/00002030-199807000-00002 Ledergerber, 1999, AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study, Jama, 282, 2220, 10.1001/jama.282.23.2220 Little, 2000, Activity of thalidomide in AIDS-related Kaposi's sarcoma, J Clin Oncol, 18, 2593, 10.1200/JCO.2000.18.13.2593 Lock, 1997, Development of a quantitative competitive polymerase chain reaction for human herpesvirus 8, J Virol Meth, 64, 19, 10.1016/S0166-0934(96)02139-8 Mellors, 1997, Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection, Ann Intern Med, 126, 946, 10.7326/0003-4819-126-12-199706150-00003 Miles, 1994, Improved survival for patients with AIDS-related Kaposi's sarcoma, J Clin Oncol, 12, 1910, 10.1200/JCO.1994.12.9.1910 Miller, 1999, Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study, Ann Intern Med, 130, 570, 10.7326/0003-4819-130-7-199904060-00005 Nunez, 2000, Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Caelyx/KS Spanish Study Group, Aids, 14, 913, 10.1097/00002030-200005260-00002 O'Brien, 1997, Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS, Ann Intern Med, 126, 939, 10.7326/0003-4819-126-12-199706150-00002 Oksenhendler, 2000, High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients, Blood, 96, 2069, 10.1182/blood.V96.6.2069 Osman, 1999, Identification of human herpesvirus 8-specific cytotoxic T-cell responses, J Virol, 73, 6136, 10.1128/JVI.73.7.6136-6140.1999 Renne, 1998, Limited transmission of Kaposi's sarcoma-associated herpesvirus in cultured cells, J Virol, 72, 5182, 10.1128/JVI.72.6.5182-5188.1998 Renwick, 1998, Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma, Aids, 12, 2481, 10.1097/00002030-199818000-00018 Rezza, 2000, Incidence of Kaposi's sarcoma and HHV-8 seroprevalence among homosexual men with known dates of HIV seroconversion. Italian Seroconversion Study, Aids, 14, 1647, 10.1097/00002030-200007280-00021 Schulz, 1998, Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8), J General Virol, 79, 1573, 10.1099/0022-1317-79-7-1573 Tirelli, 2000, Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy, Aids, 14, 1675, 10.1097/00002030-200008180-00001 Varthakavi, 1999, Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus, J Virol, 73, 10329, 10.1128/JVI.73.12.10329-10338.1999